Neurovation Labs, Inc. - Market Research Report

Company Overview

• Name: Neurovation Labs, Inc.

• Mission: Reinventing mental healthcare with precision neuromedicines by advancing a precision medicine approach to mental health disorders, starting with PTSD.

• Founded: No information is available

• Founders: No information is available

• Key People:

• Dr. Jennifer N. Perusini, Ph.D. | Chief Executive Officer

• Dr. Michael S. Fanselow, Ph.D. | Director of Research

• Richard P. Zemsky | Chief Operating Officer/Legal

• Advisors & Board Members:

• Dr. Michael W. Wood, Ph.D. | Advising Member

• Daniel G. Marren | Advising Member

• Jeremy Bloomer | Advising Member

• Dr. Kevin S. Jones, Ph.D. | Scientific Advisory Board Member

• Brigadier General (Ret.) Harris Kline | Military Advisory Board Member

• Headquarters: New York, NY, United States

• Number of Employees: No information is available

• Revenue: No information is available

• Specialization: Developing a novel drug discovery platform focusing on region-selective compounds for CNS diseases like PTSD by leveraging a deep understanding of receptor biology, neuroscience, and translational medicine.

Products

Product Offerings

1. NL-101 Series for PTSD

• Description: A small molecule Negative Allosteric Modulator (NAM) of amygdala-specific AMPA receptors aimed at the treatment of PTSD.

• Key Features:

• Region-specific targeting of TARPγ4, most expressed in the amygdala, leveraging its co-localization with AMPA receptors to achieve specificity.

2. PTSD Imaging Tracer

• Description: Utilizes the AMPA receptor/ TARPγ4 platform to develop imaging tracers with high specificity to decrease diagnostic artifacts.

• Key Features:

• Includes the patented 18F-NVL-1 radiotracer, which can detect high activity levels in the amygdala, indicating PTSD.

3. mTBI/microTBI Tools

• Description: Developed under the AMPA receptor/ TARPγ8 program to enhance imaging and diagnosis of micro Traumatic Brain Injury.

• Key Features:

• Specific targeting of TARPγ8 present in the temporal lobe and hippocampus, allowing detection of microTBI.

High-Level Product Attributes

• Precision medications aimed at treating CNS disorders at their source with minimized side effects due to their region-selective nature.

• Utilizes receptor-associated scaffolding proteins to enhance drug specificity and efficacy.

Recent Developments

• New Product Launches: No information available on new product launches.

• New Features: Focusing on the development of more targeted treating and diagnostic tools, such as radiotracers and imaging tracers, to improve PTSD diagnosis and treat TBI.

• Partnerships & Contracts:

• Awarded multiple U.S. Air Force and Army contracts to develop diagnostic and therapeutic tools for PTSD and other brain disorders.

• Recently received a Phase II contract worth $1.25M from the U.S. Air Force for advanced development of PTSD tools, indicating strong collaboration with military health systems.

Conclusion

Neurovation Labs, Inc. is focused on transforming mental healthcare, especially targeting PTSD and CNS disorders, with region-selective, precision medicines. The company aims to reduce misdiagnosis and the current inadequate therapeutic options through innovative drug discovery and development methods. Neurovation’s collaborative efforts with the U.S. military and notable advisory board members reflect strong strategic alliances and a commitment to addressing the mental health crisis with scientific advancement.